Group Version of Enhanced CBT Effective for Eating Disorders

This article originally appeared here.
Share this content:
Group Version of Enhanced CBT Effective for Eating Disorders
Group Version of Enhanced CBT Effective for Eating Disorders

WEDNESDAY, Aug. 9, 2017 (HealthDay News) -- A group version of enhanced cognitive behavioral treatment (CBT-E) is effective at reducing eating disorder psychopathology, according to a study published in the August issue of the International Journal of Eating Disorders.

Stephanie Wade, from the University of Western Australia in Perth, and colleagues randomized 40 individuals with eating disorders and a body mass index (BMI) of ≥18 kg/m² to an immediate-start or delayed-start to compare therapeutic effects of group CBT-E with a waitlist control.

The researchers found that the first eight weeks of group CBT-E were more effective at reducing Global Eating Disorder Examination Questionnaire (EDE-Q) scores than no treatment (waitlist control). A good outcome (defined as a Global EDE-Q within one standard deviation of Australian community norms plus BMI ≥18.5 kg/m²) was achieved by 67.9 percent of treatment completers. Additionally, symptom abstinence was reported by 14.3 percent of treatment completers. There were also significant improvements in clinical perfectionism, self-esteem, interpersonal difficulties, and mood intolerance.

"This study demonstrated that a group version of CBT-E can be effective at reducing eating disorder psychopathology in a transdiagnostic sample of individuals with eating disorders," the authors write. "Group CBT-E could provide a means of increasing availability of evidence-based treatment for eating disorders."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »